Ozempic & GLP-1 Lawsuit Claims

Thousands of people prescribed Ozempic, Wegovy, and Mounjaro are reporting severe stomach injuries — including a condition called gastroparesis that can cause permanent damage. If you or someone you love suffered serious gastrointestinal harm after taking a GLP-1 drug, you may qualify for compensation through an Ozempic lawsuit.

What Is the Ozempic Lawsuit?

The Ozempic lawsuit is a growing wave of personal injury cases filed against Novo Nordisk and Eli Lilly, alleging that their GLP-1 receptor agonist drugs caused severe and undisclosed gastrointestinal injuries. Plaintiffs argue the manufacturers knew — or should have known — that these drugs carry a significantly higher risk of stomach paralysis and other serious GI harms than the warning labels disclosed.

The litigation began in earnest in 2023 and has grown rapidly. As of early 2026, more than 10,000 cases have been filed in the federal court system, with a large chunk consolidated in a multidistrict litigation (MDL) in the Eastern District of Pennsylvania. Legal analysts expect the number of plaintiffs to rise as more patients connect their symptoms to their prescriptions.

This is not a frivolous wave of claims. The FDA updated the prescribing labels for semaglutide products in 2023 to add gastroparesis as a listed risk — an acknowledgment that the injury is real and linked to the drug class. These cases fit squarely within the framework of defective product claims.

Which Drugs Are Involved?

The lawsuits cover the entire class of GLP-1 receptor agonist drugs marketed for diabetes management and weight loss. The three primary drugs named most often are Ozempic, Wegovy, and Mounjaro — though other GLP-1 medications may also be relevant depending on your prescription history.

Ozempic and Wegovy share the same active ingredient, semaglutide, at different doses. Mounjaro and Zepbound share tirzepatide. If you took any of these drugs and developed a GI condition, your prescription history is worth reviewing with an attorney.

Injuries Alleged: Gastroparesis and Beyond

Gastroparesis — a condition in which the stomach empties far more slowly than normal — is the central injury alleged in this litigation. The condition is sometimes called stomach paralysis. It can cause chronic nausea, vomiting, bloating, and severe malnutrition. In serious cases, patients require feeding tubes or repeated hospitalizations.

What Makes Gastroparesis Serious

Delayed gastric emptying is not simply an upset stomach. The condition can become permanent. Some patients report that their symptoms continued — or worsened — even after they stopped taking the drug.

A 2022 study published in JAMA found that people taking semaglutide faced a 9.09 times higher risk of developing this diagnosis compared to those taking bupropion for weight loss. That finding was notable because it was not buried in manufacturer data — it came from an independent review of real-world insurance claims. The FDA updated its drug safety communications for these products as a result of emerging evidence.

Other GI Injuries in the Lawsuits

Beyond delayed gastric emptying, plaintiffs allege a range of additional GI harms. These include intestinal obstruction, severe pancreatitis, gallbladder disease, and ileus (a failure of normal intestinal movement). Some plaintiffs have required emergency surgery.

Not every injured patient developed the same diagnosis. The common thread is that manufacturers allegedly downplayed or omitted the severity of these risks in their marketing and labeling materials.

What Plaintiffs Claim Went Wrong

Manufacturers had a legal duty to warn prescribers and patients about all known material risks — and plaintiffs argue that duty was breached long before the FDA label update in 2023. The core theory is a failure-to-warn claim under product liability law.

Plaintiffs allege that internal clinical data showed elevated rates of GI complications years before the drugs went to market. They argue that Novo Nordisk and Eli Lilly prioritized commercial growth over patient safety by understating these risks in clinical trial reporting and direct-to-consumer advertising. The aggressive TV and social media campaigns for Ozempic and Wegovy drove millions of prescriptions — including prescriptions for people who were not warned adequately.

Negligence and Design Defect Claims

Some plaintiffs go beyond failure-to-warn and also bring design defect claims. They argue that the drugs as formulated carry an unreasonably dangerous risk profile — one that a safer alternative design could have avoided. These claims are harder to prove but can support larger damage awards if successful.

Negligence claims allege that the companies did not exercise reasonable care in post-market surveillance. Once early adverse event reports surfaced with the FDA, plaintiffs argue the companies should have acted faster to update their labels and notify healthcare providers.

Mass Tort vs. Class Action: What Is the Difference?

An Ozempic lawsuit is a mass tort, not a class action — and that distinction matters for what you could recover. In a mass tort, each plaintiff maintains a separate, individual case. Your damages are based on your specific injuries, your medical costs, your lost income, and your own suffering. You are not splitting a single pot with thousands of others.

In a class action, all plaintiffs share one settlement amount. Individual payouts can be small — sometimes just a few dollars — because the money is divided among the entire class. Mass torts allow for much larger individual recoveries for people with serious injuries. See our full overview of mass torts for a deeper explanation of how this litigation model works.

Who May Qualify for an Ozempic Lawsuit?

Qualifying for this litigation generally requires three things: a documented prescription for a GLP-1 drug, a diagnosis of a qualifying injury, and a causal link between the two. Here is a straightforward breakdown of who typically meets the threshold.

Basic Eligibility Criteria

• Drug use: You took Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or another GLP-1 agonist for at least four to six weeks.
• Diagnosis: You received a medical diagnosis of gastroparesis, delayed gastric emptying, ileus, bowel obstruction, pancreatitis, or a related serious GI condition.
• Timeline: Your diagnosis occurred while you were taking the drug or within a reasonable period after stopping.
• Damages: You suffered real financial or physical harm — medical bills, lost wages, hospitalization, or lasting impairment.

Who May Not Qualify

People who experienced only mild nausea or temporary side effects that resolved quickly are less likely to qualify. The cases that move forward generally involve documented medical treatment, specialist visits, or hospitalization. Pre-existing gastroparesis diagnosed before starting the drug may complicate a claim but does not automatically disqualify a plaintiff — especially if the drug clearly worsened the condition.

Statute of Limitations: How Long Do You Have?

Every state sets a deadline — called the statute of limitations — for filing a personal injury lawsuit. Miss it, and your claim is barred forever, regardless of how strong it is. In most states, the deadline for product liability claims is two to three years from the date of injury or from the date you reasonably discovered the injury was linked to the drug.

The discovery rule is especially important in this litigation. Many patients did not immediately connect their GI diagnosis to their GLP-1 prescription. Courts generally start the clock when you knew or should have known about the connection — not necessarily when you first took the drug.

Some states have shorter windows. Louisiana, for example, has a one-year prescriptive period for personal injury claims. A few states toll (pause) the statute in certain circumstances, such as when the plaintiff is a minor or when the defendant fraudulently concealed information. An attorney can tell you exactly where you stand based on your state and the facts of your case. Do not wait — check your eligibility now while your options are still open.

What Compensation May Look Like

Compensation in GLP-1 drug lawsuits typically covers medical bills, lost wages, pain and suffering, and — in egregious cases — punitive damages. The MDL is still in early stages, which means no global settlement amounts have been publicly announced. However, the categories of recoverable damages are well established under personal injury law.

Economic Damages

Economic damages are the measurable financial losses tied to your injury. These include past and future medical expenses, costs of hospitalization and surgery, lost income while you were unable to work, and the cost of ongoing treatment or therapy. For patients who developed chronic delayed gastric emptying, future care costs can be substantial.

Non-Economic Damages

Non-economic damages cover pain, suffering, emotional distress, and loss of enjoyment of life. These are harder to calculate but often represent the largest portion of a personal injury award in serious cases. States differ on whether they cap non-economic damages in product liability suits — another reason to speak with an attorney in your state.

Punitive Damages

Punitive damages are awarded in cases where a defendant's conduct was especially reckless or intentional. If plaintiffs can show that Novo Nordisk or Eli Lilly deliberately buried safety data, punitive damages could be available on top of compensatory awards. These are not guaranteed but are part of some plaintiff attorneys' legal theories in this litigation.

How to Check Your Eligibility

Eligibility screening for an Ozempic lawsuit is free, confidential, and takes only a few minutes. You answer a short set of questions about your drug use and diagnosis. No medical records are required at the screening stage.

If you appear to qualify, you will be connected with a licensed attorney in your state who handles GLP-1 drug injury cases on contingency — you pay nothing unless you recover.

What to Gather Before You Screen

Having basic information ready will speed up the process. Try to locate your prescription records, any pharmacy printouts showing the drug name and dates, and any medical records or lab reports related to your GI diagnosis. You do not need all of this to start — but the more documentation you have, the faster an attorney can evaluate your case.

Attorneys working these cases handle everything from demand letters to trial preparation. Your job at this stage is simply to describe what happened as accurately as you can. Use the eligibility check tool to get started today.

Vision Loss (NAION) Claims: A Separate Injury Track

A newer wave of Ozempic and Wegovy claims centers on NAION (non-arteritic anterior ischemic optic neuropathy), a form of sudden, usually permanent vision loss caused by reduced blood flow to the optic nerve. These claims are legally and medically distinct from the gastroparesis claims described above, and they are proceeding in their own federal litigation.

A Harvard-affiliated study first flagged the elevated risk, and the finding has since been echoed by later research: patients prescribed semaglutide medications like Ozempic and Wegovy face roughly double the risk of developing NAION compared to patients on other diabetes or weight-loss drugs. The European Medicines Agency has concluded NAION should be listed as a very rare side effect of semaglutide, estimating it may affect up to 1 in 10,000 patients. The FDA has not yet added a specific NAION warning to the Ozempic label in the United States.

MDL 3163: The Vision Loss Litigation

NAION claims are consolidated separately as MDL No. 3163, formally In re: GLP-1 Receptor Agonists NAION Products Liability Litigation, created in December 2025. As of August 2026, roughly 200 cases were pending, up from 86 in May 2026. A leadership team of plaintiff attorneys was appointed in March 2026 to organize evidence and prepare the litigation's first bellwether trials, which have not yet been scheduled.

Who May Qualify for a Vision Loss Claim

You may have a separate NAION claim if you took Ozempic, Wegovy, or another semaglutide medication and experienced sudden vision loss in one eye, typically noticed on waking, with no other identified cause such as glaucoma or a stroke. An ophthalmologist's diagnosis confirming NAION specifically, rather than a general description of vision problems, is the evidence this claim relies on.

Because this is a newer, smaller litigation than the gastroparesis track, no settlement framework or verdict yet exists to benchmark case value against. If you have both a gastroparesis diagnosis and a separate NAION diagnosis, tell your attorney about both. They may need to be evaluated, and potentially filed, as separate claims rather than one combined case.

Other Alleged Injuries and Related Litigation

Beyond gastrointestinal complications and vision impairment, several other medical conditions have surfaced in discussions surrounding glucagon-like peptide-1 (GLP-1) medications. Some claims cite warnings printed on Food and Drug Administration (FDA) approved labels, while others arise from unapproved copycat formulas. None of these additional categories has a separate multidistrict litigation (MDL) docket.

Thyroid C-Cell Tumor Allegations

Semaglutide drug packaging carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent testing. Whether this tumor risk occurs in humans remains unknown. The label contraindicates the drug for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Some individuals have filed lawsuits citing thyroid cancer alongside severe stomach injuries within the broader GLP-1 litigation. No independent MDL exists for thyroid cancer claims. Courts have not created a separate bellwether schedule or settlement structure for this specific diagnosis.

Bone Density and Osteoporosis Concerns

Bone mineral density loss and osteoporosis remain an emerging scientific topic. These concerns do not form an active lawsuit track. Rapid weight loss reduces the mechanical load on bones, causing skeletal density to decrease.

Manufacturers do not list bone density loss as a drug-specific safety warning on semaglutide labels. No court coordinates an MDL for skeletal damage. Attorneys treat this medical research as a developing area to watch.

Kidney Injury and Volume Depletion Risks

Prescribing labels for semaglutide warn that severe gastrointestinal reactions can trigger dehydration and subsequent kidney damage. Extreme vomiting and diarrhea cause volume depletion, which has been associated with acute kidney injury in some patients. Product guidelines advise doctors to monitor renal function in at-risk patients.

Acute kidney injury does not have an independent mass-tort track like gastroparesis or vision loss. Instead, plaintiffs occasionally include kidney impairment as one complication among several in broader complaints. No separate MDL exists for GLP-1 kidney claims.

Compounding Pharmacy Lawsuits and Dosing Errors

Lawsuits against compounding pharmacies and telehealth operators form a separate legal category from the main manufacturer litigation. Prolonged shortages of branded Ozempic and Wegovy prompted compounding businesses to sell unapproved versions of semaglutide. Some of these formulations used unauthorized salt forms, including semaglutide sodium and semaglutide acetate.

The FDA issued public alerts regarding dosing errors and untested chemical salts in compounded batches. Compounded semaglutide often ships in multidose vials rather than pre-measured commercial pens. Measurement confusion has led some patients to inject significant overdoses.

This litigation targets compounding facilities and telehealth prescribers instead of original drug makers like Novo Nordisk. Claims center on dosing instructions, unapproved salt mixtures, and direct physical harm from overdoses. This emerging area of litigation and regulatory action proceeds on its own timeline outside the federal MDL.

Frequently Asked Questions

Is there an Ozempic class action lawsuit I can join?

No — this litigation is structured as a mass tort, not a class action. Each plaintiff files a separate personal injury case. Your damages are based on your individual injuries, not split among a pool of thousands of other claimants. This structure generally results in higher individual recoveries for people with serious GI injuries.

What injuries qualify for a Wegovy or Ozempic lawsuit?

The injuries most commonly cited in these cases include gastroparesis (stomach paralysis), delayed gastric emptying, ileus, bowel obstruction, and severe pancreatitis. Mild or temporary nausea that resolved on its own is generally not enough. Courts look for documented diagnoses that required medical treatment.

Can I sue if I took Mounjaro instead of Ozempic?

Yes. Mounjaro (tirzepatide) and its weight-loss version, Zepbound, are named in related GLP-1 drug injury claims alongside Ozempic and Wegovy. The underlying legal theories — failure to warn, design defect, and negligence — apply to the drug class broadly. Your specific prescription history will determine which manufacturer is the appropriate defendant.

How long does it take to resolve an Ozempic lawsuit?

Mass tort MDLs typically take several years to reach resolution. The Eastern District of Pennsylvania MDL is still in early discovery phases as of mid-2026. Some early cases may settle individually before a global resolution is reached; others will go through bellwether trials, which help both sides calibrate the value of the broader litigation. Filing sooner puts you in a better position before any settlement fund is structured.

Do I need to have stopped taking the drug to file a claim?

You do not need to have stopped taking the drug to file a lawsuit. However, if your physician has advised you to continue for medical reasons, that decision is between you and your doctor. Many attorneys prefer to speak with clients who are no longer taking the drug, because it makes causation arguments cleaner, but ongoing use does not automatically bar a claim.

What is the FDA's current position on GLP-1 drug safety?

The FDA has updated the prescribing information for semaglutide products to list gastroparesis as a known risk. The agency continues to monitor adverse event reports through its MedWatch adverse event reporting program. The label update is significant because it serves as evidence that the injury risk is real and that manufacturers were on notice of the risk.

Will I have to go to court?

Most mass tort cases settle before trial. However, some plaintiffs do go to trial — particularly in bellwether cases that test how juries respond to specific fact patterns. Your attorney will walk you through all options before any hearing or trial date is set. Filing a lawsuit does not automatically mean you will appear in court.